| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0969-8051(03)00086-6 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0969805103000866?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0969805103000866?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 14499334 |
| P5875 | ResearchGate publication ID | 9089758 |
| P50 | author | George Sledge | Q92594250 |
| Kathy D. Miller | Q91794468 | ||
| P2093 | author name string | Ji-Quan Wang | |
| Qi-Huang Zheng | |||
| Xiangshu Fei | |||
| Timothy R. DeGrado | |||
| Gary D. Hutchins | |||
| George W. Sledge | |||
| Michael L. Sullivan | |||
| Bruce H. Mock | |||
| Barbara E. Glick-Wilson | |||
| K. Lee Stone | |||
| Tanya D. Martinez | |||
| Dawn J. Gay | |||
| Winston L. Baity | |||
| P2860 | cites work | Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors | Q28369255 |
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| Matrix metalloproteinases in tumour invasion and metastasis | Q33765792 | ||
| In vivo molecular target assessment of matrix metalloproteinase inhibition | Q33949202 | ||
| [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice | Q44230675 | ||
| Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor | Q44353059 | ||
| Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents | Q44472706 | ||
| Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester | Q44589894 | ||
| Improved synthesis of beta-CIT and [11C]beta-CIT labeled at nitrogen or oxygen positions. | Q51557600 | ||
| Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. | Q53668849 | ||
| A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines | Q56028298 | ||
| Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, andN-Hydroxysulfonamides Inhibit Both These Zinc Enzymes1 | Q58863326 | ||
| A simple synthesis of [11C]methyl triflate | Q67507426 | ||
| Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits | Q73589806 | ||
| Reduced angiogenesis and tumor progression in gelatinase A-deficient mice | Q74309789 | ||
| Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase | Q77743801 | ||
| Convenient gas phase bromination of [11C]methane and production of [11C]methyl triflate | Q77925202 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| molecular medicine | Q3523816 | ||
| P304 | page(s) | 753-760 | |
| P577 | publication date | 2003-10-01 | |
| P1433 | published in | Nuclear Medicine and Biology | Q7067979 |
| P1476 | title | Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester | |
| P478 | volume | 30 |
| Q38202093 | A comprehensive review on controls in molecular imaging: lessons from MMP-2 imaging |
| Q92816934 | Active-Site Targeting Paramagnetic Probe for Matrix Metalloproteinases |
| Q37139413 | Clinical biomarkers of angiogenesis inhibition |
| Q37626064 | Imaging aspects of the tumor stroma with therapeutic implications |
| Q37236103 | Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics |
| Q37687929 | Mechanism-based profiling of MMPs. |
| Q92702708 | Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs) |
| Q37710417 | Molecular Imaging of Proteases in Cancer |
| Q34496670 | Molecular imaging in cancer treatment |
| Q58816167 | Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo |
| Q38000174 | Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? |
| Q37366243 | PET Imaging of Angiogenesis |
| Q36777285 | Positron emission tomography tracers for imaging angiogenesis |
| Q30475818 | Preclinical molecular imaging of tumor angiogenesis. |
| Q44589894 | Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester |
| Q38974209 | Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy. |
| Q99708869 | The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology |
Search more.